ArticleCureus2026
Posterior Reversible Encephalopathy Syndrome in a Patient With Intrahepatic Cholangiocarcinoma: Converging Effects of Acute Hypertension and Cisplatin Therapy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posterior reversible encephalopathy syndrome (PRES) is a neurotoxic state characterized by seizures, headache, altered mental status, and characteristic posterior-predominant vasogenic edema on neuroimaging. It is frequently associated with acute hypertension, endothelial dysfunction, and exposure to cytotoxic or immunosuppressive agents. We report a case of PRES in a patient with stage IIIB intrahepatic cholangiocarcinoma receiving cisplatin-based chemotherapy who presented with new-onset generalized tonic-clonic seizures in the setting of newly diagnosed acute hypertension. Magnetic resonance imaging demonstrated posterior-predominant subcortical fluid-attenuated inversion recovery (FLAIR) hyperintensities consistent with PRES. The patient improved with strict blood pressure control, antiepileptic therapy, and supportive care. This case illustrates the contribution of coexisting risk factors, including acute hypertension and cisplatin exposure, to the development of PRES. It also highlights the need for broadened differential diagnoses, particularly in oncology patients in whom neurologic symptoms may initially be attributed to alternative etiologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.